maxivax / MaxiVAX –

Robots.txt Information

Robot	Path	Permission
GoogleBot	/	✔
BingBot	/	✔
BaiduSpider	/	✔
YandexBot	/	✔
User-agent: * Crawl-delay:

Meta Tags

Title	MaxiVAX –
Description	Latest news EU H2020 Collaborations News & media Contact & Careers EU H2020 Collaborations News & media Contact & Careers Home About us Our technology Pipeline Clinic
Keywords	N/A

Server Information

WebSite	maxivax.ch
Host IP	128.65.195.87
Location	Switzerland

Related Websites

                        Site
                        Rank
                    

More to Explore

maxivax.ch Valuation

US$490,390

Last updated: 2023-05-07 11:23:57

maxivax.ch has Semrush global rank of 21,583,463. maxivax.ch has an estimated worth of US$ 490,390, based on its estimated Ads revenue. maxivax.ch receives approximately 56,584 unique visitors each day. Its web server is located in Switzerland, with IP address 128.65.195.87. According to SiteAdvisor, maxivax.ch is safe to visit.

Traffic & Worth Estimates

Purchase/Sale Value	US$490,390
Daily Ads Revenue	US$453
Monthly Ads Revenue	US$13,581
Yearly Ads Revenue	US$162,961
Daily Unique Visitors	3,773
Note: All traffic and earnings values are estimates.

DNS Records

Host	Type	TTL	Data
maxivax.ch.	A	3598	IP: 128.65.195.87
maxivax.ch.	AAAA	298	IPV6: 2001:1600:4:b:1618:77ff:fe41:dd0d
maxivax.ch.	NS	86400	NS Record: ns2.infomaniak.ch.
maxivax.ch.	NS	86400	NS Record: ns1.infomaniak.ch.
maxivax.ch.	MX	300	MX Record: 0 maxivax-ch.mail.protection.outlook.com.
maxivax.ch.	TXT	86400	TXT Record: MS=ms41188002
maxivax.ch.	TXT	86400	TXT Record: v=spf1 include:spf.protection.outlook.com -all
maxivax.ch.	TXT	86400	TXT Record: google-site-verification=TFWKtLfkvxegMtaaD0Mx5MjGCO5yAUbeSrmC1lfJ1HQ

HtmlToTextCheckTime:2023-05-07 11:23:57

EU H2020 Collaborations News & media Contact & Careers EU H2020 Collaborations News & media Contact & Careers Home About us Our technology Pipeline Clinical trials ACTIVATE YOUR OWN DEFENSE 17.04.2023 MaxiVAX will be reporting the first results of sustained, peritumoral low-dose anti-CTLA-4 delivered by our encapsulated-cell technology in a colorectal cancer model at the AACR annual meeting 2023, in Orlando, Florida from April 14-19, 2023. Our findings suggest that a sustained, controlled delivery of low-dose aCTLA4 by our technology could bring significant therapeutic benefit, without the commonly associated severe toxicities. More information on the methodology and results can be found in the attached poster. Poster AACR annual meeting 2023 17.01.2023 MaxiVAX is pleased to announce that Dr Bruno Osterwalder, MD, former Chief Medical Officer, will become a Senior Advisor and member of MaxiVAX’s Scientific Advisory Board, as part of the planned leadership transition. Dr Osterwalder

HTTP Headers

HTTP/1.1 301 Moved Permanently
Date: Wed, 27 Oct 2021 22:29:46 GMT
Server: Apache
X-Redirect-By: WordPress
Upgrade: h2
Connection: Upgrade
Location: https://www.maxivax.ch/
Content-Type: text/html; charset=UTF-8

HTTP/2 200 
date: Wed, 27 Oct 2021 22:29:47 GMT
server: Apache
link: ; rel="https://api.w.org/"
link: ; rel="alternate"; type="application/json"
link: ; rel=shortlink
strict-transport-security: max-age=16000000
vary: Accept-Encoding
content-type: text/html; charset=UTF-8

maxivax.ch valuation and analysis